Summary of Significant Accounting Policies - Additional Information (Details) $ / shares in Units, shares in Thousands		3 Months Ended		6 Months Ended
	Jul. 01, 2015	Jun. 30, 2016 USD ($) segment $ / shares shares	Jun. 30, 2015 USD ($) shares	Jun. 30, 2016 USD ($) $ / shares shares	Jun. 30, 2015 USD ($) shares	Dec. 31, 2015 USD ($)
Line of Credit Facility [Line Items]
Common stock conversion ratio	0.125
Anti-dilutive securities excluded from computation of earnings per share amount | shares		110	521	110	297
Contract manufacturing revenue		$ 1,986,000	$ 6,003,000	$ 11,192,000	$ 10,184,000
Number of business segments | segment		1
Accounting Standards Update 2015-03 | Prepaid Expenses, Other Assets and Long Term Debt, Current
Line of Credit Facility [Line Items]
Deferred finance costs, net						$ 93,000
Accounting Standards Update 2015-03 | Other Assets and Long Term Debt, Noncurrent
Line of Credit Facility [Line Items]
Deferred finance costs, net						$ 72,000
Continuing Operations
Line of Credit Facility [Line Items]
Contract manufacturing revenue		$ (100,000)		$ 800,000
Change in estimate, effect of change on earnings per share | $ / shares		$ (0.01)		$ 0.03
Endo Ventures Supply Agreement | Minimum
Line of Credit Facility [Line Items]
Term of supply agreement				8 years
Zohydro ER and Sumavel DosePro
Line of Credit Facility [Line Items]
Period to accept returned unused product prior to expiration				6 months
Period to accept returned unused product after product expiration				12 months